Fed Circ says Indivior patent was anticipated
30-11-2021
Judge allows Dr Reddy’s to add antitrust claims in Indivior dispute
25-08-2020
PTAB institutes IPR of Nalox-1 opioid overdose treatment
29-08-2019
Piotr Swat / Shutterstock.com
The US Court of Appeals for the Federal Circuit has upheld an earlier ruling that Indivior cannot stop two competitors from making a generic version of one of its drugs.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Indivior, Dr Reddy’s, generics, Suboxone, opioid addiction, patent infringement, patent validity, US Court of Appeals for the Federal Circuit
